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Predictive Biomarkers and Personalized Medicine
High EGFR Gene Copy Number and Skin Rash as Predictive
Markers for EGFR Tyrosine Kinase Inhibitors in Patients with
Advanced Squamous Cell Lung Carcinoma
Youngjoo Lee1, Hyo Sup Shim2, Moo Suk Park3, Joo-Hang Kim3,4, Sang-Jun Ha5,
Se Hoon Kim2, and Byoung Chul Cho3,4
Abstract
Purpose: This study aimed to search for predictors of epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKI) efficacy in previously treated patients with advanced squamous cell lung carcinoma
in which EGFR mutations are very rare.
Experimental Design: EGFR gene copy numbers were assessed by FISH and evaluated as predictors of
EGFR-TKI efficacy in71patientswith advanced squamous cell lung cancerwho received gefitinibor erlotinib
as a second-line or higher therapy. The tumors were classified into EGFR/FISH-positive (high polysomy/
gene amplification) and EGFR/FISH-negative (other) groups.
Results: EGFR/FISH was positive in 19 (26.7%) patients. Only EGFR/FISH positive status was correlated
with the EGFR-TKIs response (EGFR/FISHþ vs. EGFR/FISH, 26.3% vs. 2.0%; P¼ 0.005). In a multivariate
analysis, the risk of progression was lower in EGFR/FISH-positive patients (HR of EGFR/FISHþ vs. EGFR/
FISH, 0.57; P¼ 0.057) or patients experiencing grade 2 or more rash (HR for rash grade 2 or more vs. less
than 2, 0.54; P ¼ 0.042), compared with EGFR/FISH-negative patients or those experiencing grade of less
than 2 rash, respectively. When the combined criteria of EGFR/FISH and skin rash severity were analyzed,
EGFR/FISH-negative patients with grade less than 2 rash had poorer clinical outcomes than patients with
positive EGFR/FISH or grade 2 or more rash, apparent as a lower response rate (0.0% vs. 21.4%; P¼ 0.003)
and a shorter median progression-free survival (1.13 months vs. 3.90 months; P ¼ 0.0002).
Conclusions: EGFR/FISH and skin rash severitymay be used to identify which patients are likely to gain a
benefit from EGFR-TKIs in this population. Clin Cancer Res; 18(6); 1760–8. 2012 AACR.
Introduction
The utility of molecular biomarkers in identifying the
appropriate patients for anticancer treatments has been
emphasized since the introduction of epidermal growth
factor receptor (EGFR) tyrosinekinase inhibitors (EGFR-TKI)
into the treatment of non–small-cell lung cancer (NSCLC).
Several large randomized phase III trials have verified that
EGFRmutations are the strongest predictive biomarker of the
efficacy of EGFR-TKIs as a first-line therapy (1–3). The first-
line EGFR-TKI treatment has produced greater benefits in
terms of progression-free survival (PFS), toxicity profiles, and
quality of life than standard chemotherapy in advanced
NSCLC patients with mutant EGFR, but not in those with
wild-type EGFR (1–3). Therefore, if activating mutations in
the EGFR gene are identified at the time of diagnosis, EGFR-
TKI treatment is strongly recommended as a first-line ther-
apy.However, other randomized clinical studies have shown
that even in patients with wild-type EGFR, EGFR-TKIs are
either superior to placebo or not inferior to docetaxel che-
motherapy as a second- or third-line therapy (4, 5). These
results suggest that a substantial subset of the population
without EGFR mutations can derive clinical benefit from
EGFR-TKIs as a second-line or higher treatment. In fact, these
drugs have been used in practice to treat a wide range of
NSCLCpatients, including subsets that donot include a high
proportion of EGFR mutation–positive patients. Therefore,
there is an urgent need to identify molecular or clinical
predictors of the efficacy of EGFR-TKIs, other than EGFR
mutations, in members of this population who are unlikely
to carry EGFR mutations.
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The rapid tumor cell death that occurs after treatment
with EGFR-TKIs means that the tumor is dependent on
the EGFR signaling pathway for its survival and prolifer-
ation (6, 7). Both the mutation and amplification of the
EGFR gene can fully activate EGFR tyrosine kinase and
trigger downstream oncogenic pathways. Therefore, it
seems reasonable to assume a correlation between an
abnormality in the EGFR copy number and EGFR-TKI
sensitivity. Although a number of studies have investi-
gated the EGFR copy number as a predictive biomarker
for EGFR-TKI sensitivity, its predictive role remains con-
troversial. Early studies by Hirsch and colleagues and
Capppuzzo and colleagues showed that high polysomy
or amplification of the EGFR gene was associated with
significantly greater erlotinib sensitivity and longer sur-
vival (8–11). However, other researchers failed to repli-
cate these findings (12, 13). Unlike EGFR mutations,
which are more frequently found in specific patient sub-
sets, such as East Asian, female, and never smoker
patients, and those with adenocarcinoma histology type,
the distribution of high EGFR copy numbers is mostly
independent of ethnicity, sex, smoking status, and his-
tology (9–11, 14, 15). On the basis of these findings, we
assumed that an increased EGFR copy number might be a
good candidate marker for high sensitivity to EGFR-TKIs
in EGFR wild-type tumors.
This study was designed to investigate the molecular
and clinical factors that predict EGFR-TKI efficacy in
previously treated patients with squamous cell lung car-
cinoma in which activating EGFR mutations are less than
5% (11, 16, 17). We especially focused on whether the
EGFR copy number, assessed by FISH, can identify
patients with a greater likelihood of clinical benefit from
EGFR-TKIs.
Materials and Methods
Patient selection
We first identified 102 consecutive patients who had
received gefitinib (250 mg/d) or erlotinib (150 mg/d)
monotherapy for metastatic squamous cell lung carcinoma
at the Severance Hospital (Seoul, Korea) from February
2007 to December 2010. Two pathologists (S.H.K and H.
S.S) confirmed their squamous cell carcinomaof the lungby
hematoxylin and eosin staining. The tumor samples of 71
patients were available for the examination of alterations in
the EGFR gene copy number. All the tissues had been
obtained at the time of the primary diagnosis by biopsy
(n ¼ 46; 64.8%) or surgical resection (n ¼ 25; 35.2%). The
sampling sites were the primary tumor (n ¼ 61; 85.9%) or
metastatic sites (n ¼ 10; 14.1%). The medical records and
radiographic images of the patients were then reviewed to
evaluate their clinicopathologic characteristics, tumor
responses, adverse effects, and survival outcomes using a
predesigneddata collection format. The studywas approved
by the Institutional ReviewBoard of the SeveranceHospital.
Analysis of EGFR copy number
The EGFR gene copy number was determined with FISH
testing using the LSI EGFR SpectrumOrange/CEP 7 Spec-
trumGreen Probe (Vysis; Abbott Laboratories), according to
a published protocol (15). At least 50 cells were evaluated
for each tumorby2pathologists (S.H.K. andH.S.S). Accord-
ing to previously published criteria, the EGFR gene copy
number was classified into 6 FISH strata: disomy (2 or less
copies in more than 90% of cells), low trisomy (2 or less
copies in 40% or more of cells, 3 copies in 10%–40% of
cells, 4 or more copies in less than 10% of cells), high
trisomy (2 or less copies in 40% ormore of cells, 3 copies in
40% or more of cells, 4 or more copies in less than 10%
of cells), low polysomy (4 or more copies in 10%–40% of
cells), high polysomy (4 or more copies in 40% or more of
cells), and gene amplification (defined by the presence
of tight EGFR gene clusters and a ratio of EGFR genes to
chromosomeof 2 ormore, or 15ormore copies of EGFRper
cell in 10% or more of the cells analyzed; ref. 11). Tumors
were considered EGFR/FISH positive (FISHþ) if they
showed high polysomy or amplification of the EGFR gene
with FISH.
Analysis of EGFR and KRAS mutations
A mutation analysis was carried out in the 37 patients
(52.1%) for whom adequate tissue was available. DNA was
extracted from areas of paraffin-embedded tissue samples
containing more than 70% tumor. Mutation analysis of
EGFR exons 18–21 and KRAS exons 12–13 was carried out
using a PCR-based assay described previously (18, 19).
Among the 37 patients, 13 patients were EGFR/FISH
positive.
Assessment
The tumor response was assessed by a computed tomog-
raphy scan, generally done every 8 weeks, in accordance
Translational Relevance
An epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI) has been used in practice to treat a
wide range of non–small-cell lung cancer patients,
including subsets that have a lower likelihood of EGFR
mutation. However, there have been no molecular and
clinical predictors for the efficacy of EGFR-TKIs, other
than EGFR mutations. Therefore, this study was con-
ducted to investigate predictive markers for EGFR-TKI
efficacy in previously treatedpatientswith squamous cell
lung carcinoma in which activating EGFRmutations are
very rare. Consequently, the EGFR-TKI treatment
showed the clinical benefit to squamous cell carcinoma
patients with EGFR/FISH positivity or amodest or severe
skin rash in our study. When the combined criteria of
EGFR/FISH and skin rash severity were analyzed, this
study supported the lack of benefit conferred by EGFR-
TKIs on squamous cell carcinoma patients with neither
EGFR/FISH positivity nor skin rash.
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with the guidelines established by the Response Evaluation
Criteria in Solid Tumors (20). Any treatment-related event
was graded according to the National Cancer Institute
CommonTerminologyCriteria forAdverse Events (CTCAE)
Version 3.0.
Statistical analysis
A c2 test or Fisher exact test was used to analyze the
association between EGFR copy number changes and the
radiologic tumor response and skin rash. PFS was mea-
sured from the first day of EGFR-TKI treatment until the
first documentation of disease progression or death.
Overall survival (OS) was calculated from the first day
of EGFR-TKI treatment until death or the most recent
follow-up. For the survival analysis, patients were cen-
sored at the last date at which they were known to be
alive. All time-to-event outcomes were estimated using
the Kaplan–Meier method and compared across groups
with the log-rank test or the Cox proportional hazards
model. All statistical tests were 2-sided, and statistical
significance was defined as P < 0.05.
Results
Patient and treatment characteristics
The median age was 64 years (range: 46–79 years). The
proportions of males and ever smokers were 78.9% and
81.7%, respectively. Patients had received a median of 2
prior chemotherapy regimens (range: 1–4 regimens) for
advanced disease before treatmentwith EGFR-TKIs.Half the
patients (n ¼ 35; 49.3%) received gefitinib treatment and
the other half (n ¼ 36; 50.7%) received erlotinib. Survival
data were collected until June 2011 and the median follow-
up time was 10.1 months [95% confidence interval (CI):
9.5–15.7]. At the time of analysis, 61 patients (85.9%) had
died and 8 (11.3%) had survived. Three of the survivors
were receiving EGFR-TKI treatment. For the entire patient
population, the median PFS and OS were 2.0 months
(95% CI: 1.6–2.4) and 9.5 months (95% CI: 7.3–11.8),
respectively.
According to the EGFR/FISH analysis, disomy was
present in 46 patients (64.8%), low trisomy in 1
(1.4%), high trisomy in 3 (4.2%), low polysomy in 2
(2.8%), high polysomy in 11 (15.5%), and gene ampli-
fication in 8 (11.3%). Therefore, 19 patients (26.7%)
were categorized in the EGFR/FISH-positive group and
52 patients (73.3%) in the EGFR/FISH-negative group.
The prevalence of EGFR/FISH positivity in this patient
population did not differ according to age, sex, Eastern
Cooperative Oncology group (ECOG) performance status
(PS), or smoking status (Table 1). There was no difference
in the distribution of EGFR/FISH positivity according
to the time from diagnosis to EGFR-TKI treatment or
number of previous chemotherapy regimens. EGFR/FISH
positivity was found at similar frequencies in primary
tumors and at metastatic sites. The tissue sampling
method had no effect on the pattern of FISH for the
EGFR gene.
Tumor response
Of the 69 patients available for response evaluation, 6
patients (8.7%) had a partial response, 34 (49.3%) had
stable disease, and 29 (42.0%) had progressive disease as
their best tumor response. Therefore, the objective response
rate (ORR) was 8.7% and the disease control rate was
58.0%. EGFR/FISH status was the only factor identified as
predicting the response to EGFR-TKI treatment (Fig. 1). The
EGFR/FISH-positive patients showed a significantly higher
response rate than the EGFR/FISH-negative patients (26.3%
vs. 2.0%, respectively; P ¼ 0.005). When the analysis was
limited to the 37 patients with EGFR mutation results, the
difference in response rate between 2 groups remained
unchanged (33.3% vs. 4.2%, respectively; P ¼ 0.034). A
similar trend was observed when the only EGFR wild-type
patients were analyzed (27.3% vs. 4.2%, respectively; P ¼
0.082).
Overall, 56 patients (78.9%) experienced skin rash of any
grade during EGFR-TKI treatment; 39 (54.9%) grade 1, 14
(19.7%) grade 2, and 3 (4.2%) grade 3. The incidence of
grade 2 or more rash was higher in the patients with good
ECOGPS (30.3%vs. 5.6% for ECOGPS2 and3;P¼0.053),
ever smokers (29.3% vs. 0.0% for never smokers; P ¼
0.029), and those receiving erlotinib (33.3% vs. 14.3% for
those receiving gefitinib; P¼ 0.060; Fig. 2). The EGFR/FISH-
positive patients also experienced grade2ormore rashmore
frequently than the EGFR/FISH-negative patients (42.1%
vs. 17.3%, respectively; P ¼ 0.056).
Survival outcomes
The analysis of PFS showed that both EGFR/FISH status
and skin rash severity were possible predictors of PFS after
EGFR-TKI treatment (Table 2). In the multivariate analysis,
the EGFR/FISH-positive patients had a lower risk of pro-
gression than the EGFR/FISH-negative patients, even
though the difference was borderline statistically significant
(HR of EGFR/FISHþ vs. EGFR/FISH, 0.57; 95% CI: 0.32–
1.02; P ¼ 0.057). The median PFS of the EGFR/FISH-
positive patients was higher than that of the EGFR/FISH-
negative patients [3.87 months (95% CI: 2.78–4.96) vs.
1.93 months (95% CI: 1.11–2.76); P ¼ 0.058]. When the
analysis was limited to the 37 patients with EGFRmutation
results, the difference in median PFS remained numerically
unchanged but statistically decreased [4.10 months (95%
CI: 1.66–6.54) vs. 2.10 months (95% CI: 1.21–2.99); P ¼
0.110]. The same trend was observed when the only EGFR
wild-type patients were analyzed [4.10 months (95% CI:
3.55–4.65) vs. 2.10 months (95% CI: 1.21–2.99); P ¼
0.201]. The risk of progression was significantly higher in
patients with grade less than 2 rash than in those with grade
2 or more rash (HR for rash grade 2 or more vs. less than 2,
0.54; 95%CI: 0.30–0.98; P¼ 0.042; Fig. 3B). Similar results
were observed when the analysis was limited to rash-evalu-
able population who received the drug for at least 4 weeks.
The univariate analysis of OS showed that ECOG PS,
smoking history, and skin rashwere significant predictors of
OS (Table 2). In the multivariate analysis, ECOG PS
remained an independent predictor of OS. The patients
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with ECOG PS of 0 or 1 had a significantly lower risk
of death than those with ECOG PS of 2 or 3 (HR of ECOG
PS 0–1 vs. PS 2–3, 0.34; 95% CI: 0.19–0.62; P < 0.001).
Interestingly, never smokers with squamous cell carcino-
mas had poorer survival outcomes than ever smokers with
the same histology type (HR of never smokers vs. ever
Figure 1. Objective response rates
by clinical and biomarker
characteristics. Response was
assessable in 67 patients. Statistical
differences were tested with a x2 test
or Fisher exact test. 8.7%
Female
P = 1.000 P = 0.005P = 0.690P = 1.000P = 1.000
Male Never Ever 1 2 Gefitinib Erlotinib Positive Negative
Table 1. Correlations between demographic characteristics and EGFR/FISH status
Total (n ¼ 71) Positive EGFR/FISH (n ¼ 19)
Characteristics No. (%) No./Subgroup (%) Pa
Age, y
65 40 (56.3) 9/40 (22.5) 0.357
>65 31 (43.7) 10/31 (32.3)
Sex
Female 15 (21.1) 2/15 (13.3) 0.157
Male 56 (78.9) 17/56 (30.4)
ECOG PS
0, 1 53 (74.6) 15/53 (28.3) 0.762
2, 3 18 (25.4) 4/18 (22.2)
Smoking
Never 13 (18.3) 1/13 (7.7) 0.162
Ever 58 (81.7) 18/58 (31.0)
No. of previous chemotherapy
1 30 (42.3) 6/30 (20.0) 0.260
2 or more 41 (57.7) 13/41 (31.7)
Time from diagnosis to treatment
<12 mo 52 (73.2) 15/52 (28.8) 0.511
12 mo 19 (26.8) 4/19 (21.1)
EGFR-TKI
Geﬁtinib 35 (49.3) 9/35 (25.7) 0.844
Erlotinib 36 (50.7) 10/36 (27.8)
Site of biopsy
Primary tumor 61 (85.9) 17/61 (27.9) 0.719
Metastatic sites 10 (14.1) 2/10 (20.0)
Tissue specimen
Resection 25 (35.2) 5/25 (20.0) 0.501
Biopsy 46 (64.8) 14/46 (30.4)
aTested by c2 test or Fisher's exact test.
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smokers, 1.85; 95% CI, 0.94–3.64; P ¼ 0.074). The risk of
death was numerically lower in patients experiencing grade
2 or more rash than in those experiencing grade less than 2
rash (HR for rash grade 2 or more vs. less than 2, 0.59; 95%
CI: 0.30–1.13; P ¼ 0.111).
Combined criteria of EGFR/FISH status and skin rash
grade
The treatment outcomes in the subgroups classified
according to the combined criteria of EGFR/FISH status and
grade of skin rash are shown in Table 3 and Fig. 3C. The
group of EGFR/FISH-negative patients with low-grade skin
rash had poorer clinical outcomes than the groups with
EGFR/FISH positivity or high-grade skin rash: with lower
ORR (0.0% vs. 21.4%, respectively; P ¼ 0.003), shorter
median PFS [1.13 months (95% CI: 0.40–1.86) vs. 3.90
months (95%CI: 3.45–4.35), respectively;P¼0.0002)], and
shorter median OS [4.20 months (95% CI: 0.61–7.79) vs.
9.43months (95%CI: 5.67–13.20), respectively;P¼ 0.007].
EGFR and KRAS mutations
One patient (2.7%) had amutant type EGFR gene, which
was deleted at exon 19. The tumor sample was from resec-
tion of primary tumor at T3N1M0 stage. The other patient
(2.7%) had a KRAS mutation (G12D type). The sample of
this patient was from biopsy of primary tumor at the
diagnosis of advanced stage NSCLC. The EGFR gene was
also amplified in the patient harboring the activating EGFR
mutation. Therefore, the proportion of patients with acti-
vating EGFR mutations among the EGFR/FISH-positive
group was 8.3%.
The patient with the EGFR mutant tumor was a 71-year-
old womanwho had never smoked in her life. She achieved
a partial response to gefitinib treatment and her PFS was
Table 2. Survival analysis
PFS OS
Univariate Multivariate Univariate Multivariate
Variables HR (95% CI) Pa HR (95% CI) Pa HR (95% CI) Pa HR (95% CI) Pa
Age 65 vs. >65 1.67 (0.90–2.84) 0.106 1.49 (0.88–2.51) 0.139
Female vs. male 1.09 (0.59–2.02) 0.782 1.25 (0.68–2.28) 0.468
ECOG PS 0, 1 vs. 2, 3 0.86 (0.48–1.55) 0.662 0.32 (0.18–0.58) <0.001 0.34 (0.19–0.62) <0.001
Never vs. ever smoker 1.47 (0.75–2.88) 0.256 2.27 (1.14–4.13) 0.019 1.85 (0.94–3.64) 0.074
1 vs. 2 previous chemotherapy 0.95 (0.58–1.56) 0.849 0.99 (0.59–1.64) 0.941
Geﬁtinib vs. erlotinib 1.19 (0.73–1.96) 0.488 1.20 (0.72–2.01) 0.488
EGFR/FISHþ vs. FISH 0.59 (0.33–1.03) 0.064 0.57 (0.32–1.02) 0.057 0.65 (0.37–1.56) 0.144
Skin rash grade 2 vs. <2 0.56 (0.32–0.99) 0.046 0.54 (0.30–0.98) 0.042 0.47 (0.25–0.87) 0.016 0.59 (0.30–1.13) 0.111
aTested with the Cox proportional hazards model.
23.9%
P = 0.060 P = 0.056P = 0.505P = 0.029P = 0.053
0.1 2.3 Never Ever 1 2 Gefitinib Erlotinib Positive Negative
 
(%
)
Figure 2. Grade 2 or 3 skin rash
rates according to clinical and
biomarker characteristics.
Statistical differences were tested
with a c2 test or Fisher exact test.
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19.0 months. However, the patient carrying the KRAS
mutation, a 73-year-old woman with no smoking history,
was EGFR/FISH negative. Her best response to gefitinib was
PD and her PFS was 2.0 months.
Discussion
Squamous cell carcinoma accounts for about 25% of
NSCLC (21), but recent advances in personalized treat-
ments with targeted biologic agents, including agents that
target mutant kinases such as EGFR, ALK, and HER2, the
antiangiogenic agent bevacizumab, and the multitargeting
antifolate pemetrexed, are not applicable to this histologic
type of NSCLC. However, in the BR.21 trial, erlotinib
showed a survival advantage over the best supportive care
as salvage therapy in the subgroup of patients with non-
adenocarcinoma histology (HR¼ 0.81; 95%CI: 0.64–1.02;
ref. 22). The INTEREST study also reported that there was
no survival difference between gefitinib and docetaxel treat-
ments in patients with nonadenocarcinoma who had failed
1 to 2 previous regimens (median OS, 6.4 months vs. 6.9
months, respectively; ref. 5). The placebo-controlled phase
III SATURN study also showed that maintenance erlotinib
after first-line chemotherapy had OS benefits in the stable
group, even among squamous cell carcinoma patients (HR
¼ 0.67; 95% CI: 0.48–0.92; ref. 23). These findings provide
some evidence of the clinical utility of EGFR-TKIs as salvage
therapy in patients with squamous cell carcinoma. How-
ever, there is no predictive marker for EGFR-TKI sensitivity
other than EGFRmutations, in patients with this histologic
type. Moreover, this population has very low frequency of
activating mutations of EGFR gene (about 5%;
refs. 11, 16, 17). To the best of our knowledge, this study
is the first designed to look for predictive markers appro-
priate for squamous cell carcinoma patients.
In this study, we have shown that a significant proportion
of squamous cell lung carcinoma have genomic gain in the
EGFR gene without mutational event. The EGFR/FISH-pos-
itive patients showed a significantly higher response rate
than the EGFR/FISH-negative patients. Moreover, the
patients with EGFR/FISH-positive tumors had longer PFS
than those with EGFR/FISH-negative tumors, although this
difference was marginally significant after the appropriate
adjustments. A modest or severe skin rash after EGFR-TKI
treatment was also a good predictor of longer PFS. There-
fore, this study supports that EGFR-TKIs may give the
clinical benefit to squamous cell carcinoma patients with
EGFR/FISH positivity or a modest or severe skin rash.
The association between the mutation and amplification
of the EGFR gene has been studied exclusively in the
adenocarcinoma subtype of tumors (24, 25). Many pre-
clinical and clinical data have shown that the EGFR
amplification usually coexists with mutations in lung ade-
nocarcinomas (24, 25). This observation supports the idea
that the mutation occurs first and then induces gene ampli-
fication during tumor progression and metastasis. The
IPASS study was a landmark study that showed the supe-
riority of first-line gefitinib to chemotherapy in terms of PFS
A
B
Median PFS
(mo)
EGFR/FISH– (n = 52) 1.93
EGFR/FISH+ (n = 19) 3.87
Log-rank test , P = 0.058 
Median PFS
(mo)
Rash G ≥ 2 (n = 17) 3.80
Rash G < 2 (n = 54) 1.97
Log-rank test , P = 0.041 
C Median PFS(mo)
EGFR/FISH+ or
Rash G ≥ 2 (n = 28) 3.90
EGFR/FISH– and 
Rash G < 2 (n = 43) 1.13
Log-rank test , P = 0.0002 
Figure 3. PFS curves for the 2 groups according to (A) EGFR/FISH status,
(B) skin rash grade, and (C) the combined criteria of EGFR/FISH status
and skin rash grade in 71 patients with advanced squamous cell lung
cancer, receiving geﬁtinib or erlotinib as the second-line or higher
therapy.
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in never smoker or light ex-smoker Asian patients with lung
adenocarcinoma (1). It reported a concordance between the
mutation and high gene copy number of EGFR in 88.9% of
patients and showed that the predictive value of the EGFR
copy number was driven by coexisting EGFR mutations
(26). In that study, patients with a high EGFR gene copy
numbers had significantly longer PFS when treated with
gefitinib than when treated with chemotherapy in the
presence of an EGFR mutation (HR ¼ 0.48; 95% CI:
0.34–0.67), but shorter PFS in the absence of an EGFR
mutation (HR ¼ 3.85; 95% CI: 2.09–7.09), whereas
patients with mutant EGFR had longer PFS after gefitinib
therapy irrespective of the EGFR copy number (26). How-
ever, in our study, a significant proportion of squamous cell
carcinoma patients had an amplified EGFR gene with no
mutation, and yet a high EGFR gene copy number was
correlated well with responsiveness to EGFR-TKI and PFS
benefit. This finding suggests that an amplified wild-type
EGFR tumor is also dependent on the EGFR signaling
pathway for growth, although to a lesser extent, than tumors
with amplified mutant EGFR genes. Consequently, the
number of EGFR gene copy could be considered as an
alternative molecular predictive marker of EGFR-TKI effica-
cy in EGFR wild-type population.
Our analyses have also shown a relationship between the
severity of the skin rash and survival improvement, which is
consistent with previous studies reporting that the skin rash
can be a surrogate marker of the clinical benefits of EGFR-
TKIs, regardless of the EGFR status (27, 28). Moreover, the
grade of skin rash seemedmore significant in predicting the
risk of progression than the EGFR/FISH status through the
multivariate analysis. However, it should be carefully inter-
preted because of the relatively too small sample size to
ensure the statistical significance. At the subgroup analysis,
EGFR/FISH-negative patients with high-grade skin rash
showed a lower ORR, but similar PFS and longer OS time,
compared with EGFR/FISH-positive patients with low-
grade skin rash. This result means that the patients
experiencing high-grade skin rash may have a better prog-
nosis regardless of tumor shrinkage. Some previous studies
also have explained that a significant skin reaction may
indicate the ability of a patient to raise an immune-medi-
ated inflammatory response to drug rather than more
effective target receptor inhibition (29). Therefore, the
EGFR/FISH status and skin rash severity are likely to play
a role as predictive markers of EGFR-TKIs by different
mechanisms. When we combined EGFR copy number and
skin rash as a tumor- and host-related predictive factor,
respectively, either an amplified EGFR gene or a significant
skin rash was shown as a potential positive predictor of
benefit from EGFR-TKI treatment.
There are conflicting results in the literature about the
predictive role of EGFR gene copy number (8–13). These
may be attributable to interobserver variability in FISH
testing and interpretation. Alternatively, the EGFR gene
copy status may be altered intrinsically or extrinsically
during the course of the disease. Compared with EGFR
mutations, EGFR amplification occurs as a late event during
the progression of lung adenocarcinoma, in association
with the invasive growth of the tumor (24). Therefore, there
might be discrepancies in the EGFR gene copy number
between time points because most studies, including our
own, have analyzed tissue samples acquired at the time of
the primary diagnosis rather than at the time of treatment.
However, one study by Cappuzzo and colleagues reported
the concordance between these time points in 88.9% of
patients for both EGFR FISH andmutation biomarkers (P¼
0.01 and P ¼ 0.001, respectively; ref. 8). In addition, it
remains unknown whether EGFR amplification is homo-
geneously distributed within a primary tumor or both in a
primary tumor and metastases. A lack of this information
about the time and place concordance of EGFR gene ampli-
fication seems a significant limitation for deciding on
whether EGFR FISH can be used as a reliable biomarker in
clinical setting.
In conclusion, EGFR/FISH status can be used to select
those patients with previously treated squamous cell lung
cancer who are likely to gain a benefit from EGFR-TKIs
before treatment. In addition, the high grade of skin rash
development during EGFR-TKIs in this histologic group
Table 3. Treatment outcome by combined criteria: EGFR/FISH status and skin rash grade
FISH and
rash G < 2
FISH and
rash G  2
FISHþ and
rash G < 2
FISHþ and
rash G  2
FISHþ or
rash G  2
Pa
No. of responder/total 0/41 1/9 3/11 2/8 6/28 —
ORR, % 0.0 11.1 27.3 25.0 21.4 0.003b
Median PFS, mo (95% CI) 1.13 (0.40–1.86) 4.30 (2.84–5.76) 4.10 (3.50–4.70) 3.07 (0.53–5.61) 3.90 (3.45–4.35) —
HR of progression (95% CI) 1.00 0.30 (0.13–0.67) 0.32 (0.14–0.70) 0.53 (0.24–1.16) 0.36 (0.21–0.64) <0.001c
Median OS, mo (95% CI) 4.20 (0.61–7.79) 11.03 (6.36–15.71) 7.07 (1.49–12.64) 9.17 (3.16–15.17) 9.43 (5.67–13.20) —
HR of death (95% CI) 1.00 0.51 (0.22–1.18) 0.68 (0.33–1.42) 0.44 (0.19–1.009) 0.55 (0.32–0.94) 0.028d
aStatistical difference between 2 groups ([FISHþ or rash G  2] and [FISH and rash < G2]).
bTested with Fisher's exact test.
cTested with the Cox proportional hazards model.
dTested with the Cox proportional hazards model adjusted for ECOG performance status.
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may help to support the continuous use of EGFR-TKIs.
However, because of the limitations of our study, a single
retrospective study with a relatively small number of
patients, future prospective studies should be conducted
to validate our findings.
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